Core Viewpoint - Advanced Biomed (ADVB) has agreed to sell its wholly owned subsidiary, Advanced Biomed Limited, for a total purchase price of $23,000, based on a valuation report [1] Group 1: Transaction Details - The sale involves 100% of the issued and outstanding shares of Advanced Biomed Limited, a Hong Kong company [1] - The transaction is subject to the terms and conditions outlined in the Agreement [1] - The closing of the transaction is set for December 23, with all intellectual property owned by the Hong Kong subsidiary being transferred to the buyer [1] Group 2: Intellectual Property Transfer - All intellectual property owned by Advanced Biomed Limited, including that of its wholly owned subsidiary Shanghai Sglcell Biotech, was included in the sale [1]

Group 1 - Advanced Biomed Inc. has entered into an agreement to sell 100% of its Hong Kong subsidiary for a total purchase price of US$23,000 based on a valuation report [1] - The transaction includes the transfer of all intellectual property owned by the Hong Kong subsidiary, including that of its wholly owned subsidiary, Shanghai Sglcell Biotech Co., Ltd. [2] - The CEO of Advanced Biomed stated that the divestment is part of a strategic realignment to centralize clinical trials in Taiwan due to evolving regulatory requirements in China [3] Group 2 - The company operates through its Taiwan subsidiary, which has developed a proprietary microfluidic platform for advanced circulating tumor cell detection and analysis [4] - The product portfolio includes devices and biochips designed for cancer screening, diagnosis, treatment selection, and prognosis assessment, with regulatory clearances in progress in Taiwan and plans for global expansion [4]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-42548 Advanced Biomed Inc (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organizati ...

Core Viewpoint - Chinese concept stocks experienced significant gains, with notable increases in share prices for several companies, indicating a positive market sentiment towards these stocks [1] Group 1: Stock Performance - Kuke Music (KUKEY) saw a remarkable increase of 120%, closing at 0.1100, with a trading volume of 4,794.6 thousand [1] - BQ (波奇宠物) rose by 113.73%, closing at 16.970, with a trading volume of 6,299.85 thousand [1] - Meiyantang (美妍堂) increased by 45.04%, closing at 27.760, with a trading volume of 1,703.51 thousand [1] - Advanced Biomed (ADVB) experienced a rise of 24.56%, closing at 0.5671, with a trading volume of 1,576.66 thousand [1] - Blue Mountain Holdings (BMHL) gained 22.80%, closing at 3.770, with a trading volume of 3.75 thousand [1]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of registrant as specified in its charter) Nevada 87-2177170 (State or other jurisdiction of incorporation or organization) For the fiscal year ended June 30, 2025 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to ___________________ Commission ...

Core Insights - Advanced Biomed Inc. has launched the A+PerfusC system, a compact 3D cell culture incubator designed to replicate human physiological conditions in vitro [1][2] - The A+PerfusC platform integrates automated perfusion with environmental control, allowing for up to 12 days of continuous, hands-free culture, which enhances cell viability and drug response predictability [2][5] - The global 3D cell culture market is projected to grow from USD 2.32 billion in 2025 to over USD 4.71 billion by 2030, with a compound annual growth rate of over 15.6% [4] Company Overview - Advanced Biomed Inc. specializes in innovative biomedical technologies for cancer detection and precision medicine, operating through subsidiaries in Taiwan, Hong Kong, and Mainland China [9][10] - The company has developed a proprietary microfluidic platform for advanced circulating tumor cell detection, with regulatory clearances in progress in China and plans for global expansion [10] Product Features - The A+PerfusC system supports up to 8 independent channels per plate, allowing for 600 tumor spheroids per row and a total of 4,800 tumor spheroids per plate [8] - The system is designed for easy transfer into 96 or 384 well plates for high-throughput drug screening and can be mounted on microscopy platforms [8] Future Plans - The company plans to scale up the A+PerfusC system for high-throughput use and integrate imaging with AI-driven analytics to enhance tumor profiling and personalized treatment development [5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Exact name of registrant as specified in its charter) Nevada 87-2177170 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-42548 Advanced Biomed Inc | Title of Each Class: | Trading Symbol(s): | ...

As filed with the United States Securities and Exchange Commission on February 7, 2025. Registration No. 333-272110 Advanced Biomed Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 16 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Nevada 8071 87-2177170 (I.R.S. Employer Ide ...

As filed with the United States Securities and Exchange Commission on January 27, 2025. Registration No. 333-272110 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 15 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Advanced Biomed Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Nevada 8071 87-2177170 (I.R.S. Employer Ide ...

As filed with the United States Securities and Exchange Commission on January 7, 2025. Registration No. 333-272110 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 14 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Advanced Biomed Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Nevada 8071 87-2177170 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Iden ...